Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alverine in cirrhotic portal hypertension
NCT05508633Phase 2Enrolling by invitation
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alverine in Portal Hypertension (PH), sponsored by Shanghai Changzheng Hospital. Started Oct 2022; status: enrolling by invitation.
02
Drugs
alverine
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT05508633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508633.